Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BI 1358894 in post-traumatic stress disorder
MOH_2023-03-28_012417Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing BI 1358894 125 mg with Matching placebo (2 arms). Primary endpoint: Change from baseline in CAPS-5 total severity score at week 8. Started Mar 2023; status: recruiting.
02
Drugs
bi 1358894
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on MOH_2023-03-28_012417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-28_012417.